Verastem, Inc. · NASDAQ:VSTM
Verastem — Q3 2025 Earnings Presentation
64 slides from Verastem's earnings presentation, Nov 4, 2025
Slide 1: Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | November 2025
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation includes forward - looking statements about, among other things, Verastem Oncology’s (the “Company”) programs an d product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIF
Slide 3: Commercial Product and Pipeline Positioned to Deliver Long-Term Shareholder Value
3 3 Commercial Product and Pipeline Positioned to Deliver Long - Term Shareholder Value • Strong commercial launch execution and broad HCP adoption • AVMAPKI FAKZYNJA CO - PACK is the first - ever FDA approved therapy specifically for KRAS - mutated recurrent low - grade serous ovarian cancer (LGSOC
Slide 4: Strong First Full Quarter Launch of AVMAPKI FAKZYNJA CO-PACK
4 Strong First Full Quarter Launch of AVMAPKI FAKZYNJA CO - PACK Please see the full Prescribing Information for more information PDUFA: Prescription Drug User Fee Action $11.2 million Of net product revenue in Q3 2025 FDA Approval Nearly Two Months Ahead of PDUFA Date Consistent Adoption Among Acad
Slide 5: Anticipated Milestones
5 Anticipated Milestones FDA Approved Phase 3 Phase 2 Phase 1 Regimen Trial Name/ Therapeutic Area Asset RAF/MEK Clamp + FAKi RAMP 201, recurrent LGSOC Avutometinib + Defactinib Expect to complete enrollment of IDMC - recommended increase by Q1 2026 RAF/MEK Clamp + FAKi vs ICT RAMP 301, recurrent LG
Slide 6: Continued Progress Across All Key Milestones
6 Continued Progress Across All Key Milestones RAMP 301 Completed planned enrollment in the Phase 3 confirmatory study. Reported IDMC recommendation in Q4 2025. RAMP 201J Reported initial data from Phase 2 clinical trial being conducted in Japan in Q4 2025. RAMP 203 Report an interim data update on
Slide 7: A Look Ahead
7 A Look Ahead RAMP 301 Expect to complete modest IDMC recommended patient enrollment increase in Q1 2026 RAMP 205 Expect to report an update on the safety and efficacy of the expansion cohort in 1H 2026 Continued strong execution of product launch VS - 7375 - 101 Monotherapy Plan to report an inter
Slide 8: Commercially launched in the U.S. for KRAS-mutated recurrent LGSOC
8 Commercially launched in the U.S. for KRAS - mutated recurrent LGSOC FDA Approval Date: May 8, 2025
Slide 9: Providing More Complete Blockade of RAS/MAPK Pathway Signaling
9 1. AACR Genie v16.1; 2. Cheasley et al., J Pathol 2021; 3. Thomson et al., Gynecol Oncol 2023; 4. Gershenson et al., Gynecol Oncol 2022; 5. Coma et al., AACR 2022 ; 6. Ishii et al., Cancer Res, 2013 ; 7. Lito et al., Cancer Cell, 2014 ; 8. Lubrano et al., AACR 2024 ; 9. Banerji et al., AACR 2020 ;
Slide 10: High Unmet Need for an Effective and Tolerable Therapy in Recurrent LGSOC
10 High Unmet Need for an Effective and Tolerable Therapy in Recurrent LGSOC • U.S. incidence / prevalence : 1k - 2k 1 / 6k - 8k 2 • LGSOC affects younger women with bimodal peaks of diagnosis at ages between 20 - 30 and 50 - 60; disproportionately impacts health, fertility, and long - term quality
Slide 11: Highly Targeted Approach Aimed to Drive a Successful Commercial Launch
11 Highly Targeted Approach Aimed to Drive a Successful Commercial Launch Effectively reach healthcare providers Top 100 commercial healthcare organizations contribute ~50% of patient claims 1 Engage and support patients Patients likely have progressed through other therapies, and many will be ready
Slide 12: Continued Launch Momentum in Q3 2025
12 Continued Launch Momentum of AVMAPKI FAKZYNJA CO - PACK in Q325 Please see the full Prescribing Information for more information Source: VSTM DOF $11.2 million Of net product revenue in Q3 2025 133 Prescribers 65% Rx generated by top 100 organizations 60% Rx coming from GynOncs ; 40% from MedOncs
Slide 13: Breadth and Reach Continue to Drive Impressive Results
13 Breadth and Reach Continue to Drive Impressive Results x Prescriptions coming from a mix of academic and community physicians x Seeing both repeat prescriptions and refills x Payer mix is a combination of commercial and Medicare Effectively reach healthcare providers Engage and support patients E
Slide 14: NCCN Submission for Treatment Guideline Inclusion Under Review
14 NCCN Submission for Treatment Guideline Inclusion Under Review for the Entire Population Enrolled in RAMP 201 Study NCCN Category 3 NCCN Category 2b NCCN Category 2a NCCN Category 1 General % Commercial Payer Coverage Binimetinib • Study stopped early due to futility • 16% ORR byBICR • 31% discon
Slide 15: Continuing Medical Progress in LGSOC
15 Continuing Medical Progress in LGSOC
Slide 16: 82% Had a Reduction in Target Lesions in RAMP 201
16 Across Patients With and Without KRAS Mutations in RAMP 201, 82% had a Reduction in Target Lesions while Receiving Avutometinib and Defactinib Source for all data: RAMP 201 data cut off as of June 30, 2024; Responses for 3 patients (KRAS wild type, n=1; KRAS mutant, n =2) were unknown Best Overal
Slide 17: RAMP 301: International Phase 3 Confirmatory Trial in Recurrent LGSOC
17 *US FDA analysis plan will evaluate PFS independently in KRAS - mt and KRAS wt LGSOC. BICR: blinded independent central review; BID: twice a day; BIW: twice a week; DCR: disease control rate; DoR : duration of response; INV: investigator; KRAS: kirsten rat sarcoma virus; MEKi : MEK inhibitor; mt:
Slide 18: Next Steps in LGSOC Clinical Program
18 Next Steps in LGSOC Clinical Program Continue to advance regulatory pathway in Japan and Europe Expect to complete modest IDMC recommended patient enrollment increase in Q1 2026
Slide 19: VS-7375, oral KRAS G12D (ON/OFF) Inhibitor
VS - 7375, oral KRAS G12D (ON/OFF) Inhibitor 19
Slide 20: KRAS G12D is the Most Frequent KRAS Mutation in Human Cancers
20 Adapted from Hofmann et al., Cancer Discovery 2022 • The only approved KRAS inhibitors target KRAS G12C, which is largely restricted to NSCLC • KRAS G12D accounts for 26% of all KRAS mutations • KRAS G12D mutations are especially prevalent in pancreatic and colorectal cancers • Targeting KRAS G12
Slide 21: VS-7375 is a Potent KRAS G12D Dual ON/OFF Inhibitor
21 VS - 7375 is a Potent KRAS G12D Dual ON/OFF Inhibitor GEF GTP GDP GTP GDP VS - 7375 RAS/MAPK pathway signaling GEF: Guanine nucleotide exchange factor GAP: GTPase - activating protein GAP P KRAS G12D OFF (inactive) KRAS G12D ON (active) Assay VS - 7375 IC 50 ( nM ) KRAS G12D State RAF1 binding 2
Slide 22: VS-7375 Potently and Selectively Inhibits 3D Proliferation of KRAS G12D Cell Lines
22 VS - 7375 Potently and Selectively Inhibits 3D Proliferation of KRAS G12D Mutant Cell Lines VS - 7375 IC50 (nM) KRAS status Cell Line 8 G12D SKLU1 2 G12D KP4 2 G12D GP2D 7 G12D HPAC 5 G12D HPAF - II 7 G12D AsPC1 8 G12D Panc08.13 7 G12D LS513 33 G12D LS180 63 G12D Panc04.03 133 G12C MiaPaca2 1471
Slide 23: VS-7375 is More Efficacious Than G12D ON and Pan-RAS ON Inhibitors
23 VS - 7375 (G12D ON/OFF inhibitor) is More Efficacious Than G12D ON and Pan - RAS ON Inhibitors in KRAS G12D Mutant Tumor Models KP4 Pancreatic Cancer Model LU0876 NSCLC PDX Model -100 0 100 200 500 1000 1500 2000 R e s p o n s e @ D a y 2 0 ( % c h a n g e f r o m b a s e l i n e ) v e h i c l e
Slide 24: Variant-Selective KRAS Inhibitors Spare T Cell Proliferation
24 Variant - Selective KRAS Inhibitors Spare T Cell Proliferation in Contrast to RAS - Multi Inhibitor 0.1 1 10 100 1000 0 20 40 60 80 100 Concentration (nM) C e l l P r o l i f e r a t i o n ( % c o n t r o l ) VS-7375 RMC-9805 RMC-6236 VS-7375 RMC-9805 RMC-6236 CD8+ 0.1 1 10 100 1000 0 20 40 60 80
Slide 25: GFH375 in NSCLC: Patient Characteristics (WCLC 2025)
25 Source: GenFleet Therapeutics WCLC 2025 Mini Oral Presentation September 7. 2025; Efficacy and Safety of GFH375 in Advanced N on - Small Cell Lung Cancer Patients with KRAS G12D Mutation. WCLC 2025 Cut - off date: 01 August 2025. NSCLC at 600 mg QD (n=16) All NSCLC (n=28) 4 (25.0) 12 (42.9) Disco
Slide 26: GFH375 in NSCLC: Efficacy (WCLC 2025)
26 Source: GenFleet Therapeutics WCLC 2025 Mini Oral Presentation September 7. 2025; Efficacy and Safety of GFH375 in Advanced N on - Small Cell Lung Cancer Patients with KRAS G12D Mutation. WCLC 2025 600mg QD (N=16) All patients (N=26) 68.8% [41.3%, 89.0%] 57.7% [39.8%, 74.2%] ORR [90% CI] 93.8% [6
Slide 27: WCLC 2025 GFH375: Safety Data in All Patients
27 WCLC 2025 GFH375: Safety Data in All Patients from the GenFleet Phase 1/2 Study Source: GenFleet Therapeutics WCLC 2025 Mini Oral Presentation September 7. 2025; Efficacy and Safety of GFH375 in Advanced N on - Small Cell Lung Cancer Patients with KRAS G12D Mutation. • 142 patients, including 28
Slide 28: GFH375: Safety Data in All Patients from the GenFleet Phase 1/2 Study
28 WCLC 2025 Source: GenFleet Therapeutics WCLC 2025 Mini Oral Presentation September 7. 2025; Efficacy and Safety of GFH375 in Advanced N on - Small Cell Lung Cancer Patients with KRAS G12D Mutation. Abbreviations: ALT, alanine transaminase; AST, aspartate transferase; TRAE, treatment related adver
Slide 29: GFH375 PDAC Baseline Characteristics
29 GFH375 600 mg QD (N=66) 60 (35, 74) Age, median (range), years 35 (53.0%) ≥ 60, n (%) 35 (53.0%) Male, n (%) 66 (100%) ECOG PS 1, n (%) Histological type, n (%) 64 (97.0%) Adenocarcinoma 2 (3.0%) Adenosquamous carcinoma 63 (95.5%) Stage IV at study entry, n (%) c Baseline metastasis, n (%) 52 (78
Slide 30: GFH375: Best Overall Response (PDAC)
30 GFH375: Best Overall Response (PDAC) Changes from baseline in target lesions 20 50 0 - 30 - 5 0 0 100 200 300 Time since study treatment initiation (days) 20 - 30 Best % changes from baseline in target lesions - 50 0 N=59 40.7% [30%, 52%] ORR [90%CI] Best overall response, n (%) 24 (40.7) Partial
Slide 31: GFH375: Progression-Free Survival (PDAC)
31 GFH375: Progression - Free Survival (PDAC) ESMO 2025 • Median PFS was 5.52 months ( 90%CI: 4.27, 7.20), with a median follow - up time 5.65 months ( 90%CI: 4.96, 6.08 ). • 4 - month PFS rate was 78.2% ( 90%CI: 69.8%, 87.5%). Source: GenFleet Therapeutics. Data cut - off date: September 27, 2025.
Slide 32: GFH375: Overall Survival (PDAC)
32 GFH375: Overall Survival (PDAC) ESMO 2025 • Median OS was not reached with a median follow - up time 5.65 months (90%CI: 5.22, 6.14). • 4 - month OS rate was 92.2% (90%CI: 86.8%, 97.9%). Source: GenFleet Therapeutics. Data cut - off date: September 27, 2025. All patients received first dose of GF
Slide 33: GFH375: Safety Overview (PDAC)
33 GFH375: Safety Overview (PDAC) • GFH375 presented a manageable safety profile at 600mg QD in previously heavily treated KRAS G12D mutant PDAC patients. • All patients experienced at least one TEAE and TRAE. • No fatal TRAE. Grade 3 TRAEs occurred in 20 patients (30.3%) and a grade 4 TRAE occurred
Slide 34: GFH375: Common Adverse Events (PDAC)
34 GFH375: Common Adverse Events (PDAC) ESMO 2025 • The safety profile of GFH375 in KRAS G12D mutant PDAC patients is consistent with previous report 1,2 – Common TRAEs were gastrointestinal and hematological AEs; most were grade 1 or 2 and manageable with supportive treatment – Most frequent TRAEs
Slide 35: GFH375 PDAC Waterfall Plot Notes
35 Source: GenFleet Therapeutics Oct. 27, 2025. Data cut - off date: September 27, 2025. All participants received first dose of GFH3 75 for at least 4 months prior to the cut - off date. Seven participants had no post - treatment tumor assessments due to early dropout: 2 due to AEs not related to G
Slide 36: GFH375 Breakdown of PDAC Safety Data (Post ESMO Update)
36 GFH375 600mg QD 2L+ PDAC, N=66 Grade ≥ 3 Any grade Gastrointestinal disorders 3.0% 56.1% Diarrhea 1.5% 47.0% Vomiting 0 47.0% Nausea 3.0% 33.3% Decreased appetite Hematological toxicities 7.6% 48.5% Neutrophil count decreased 7.6% 42.4% Anemia 1.5% 36.4% WBC count decreased 1.5% 28.8% PLT decreas
Slide 37: Accelerated Development Approach Builds on First-in-Human Findings
37 • Efficacious starting dose: • 400 mg QD starting dose supported by monotherapy efficacy/safety in FIH study • Evaluating GI side effect mitigations: • Use prophylactic anti - emetics • Evaluate dosing with and without food • Evaluate additional formulation • Multiple, high - value indication str
Slide 38: VS-7375 Study Schema
38 VS - 7375 - 101 Study Schema, Efficiently Testing KRAS G12D+ Indications with Monotherapy and SOC Combinations Part A: Single Agent Dose Escalation – Any KRAS G12D Solid Tumor Cohort B1: 2L+ PDAC (N=20) Cohort D1: 2L+ CRC Cetuximab (N=20) VS - 7375 + Combinations Part B: Dose Expansion Part C: Co
Slide 39: VS-7375 Clears Two Dose Levels, Demonstrates Promising Anti-Tumor Activity
39 Source: Verastem press release Oct. 23, 2025; VSTM DOF VS - 7375 Clears Two Dose Levels, Demonstrates Promising Anti - Tumor Activity in Ongoing Phase 1/2a Trial Monotherapy Dose Escalation GI Adverse Events Combination Cohorts First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared,
Slide 40: Next Steps in VS-7375 Clinical Program
40 Next Steps in VS - 7375 Clinical Program Q4 2025 1H 2026 • Plan to report an interim safety and efficacy update on the Phase 1/2a trial of VS - 7375. ௗ • Expect to select the RP2D and plan to initiate monotherapy expansion cohorts in advanced PDAC, NSCLC, and other KRAS G12D - mutated solid tumor
Slide 41: Topline Data from RAMP 205 in First-Line Metastatic Pancreatic Cancer
Topline Data from RAMP 205: Avutometinib + Defactinib + Standard of Care in First - Line Metastatic Pancreatic Cancer
Slide 42: PDAC Represents an Area of High Unmet Need
42 1 SEER 12; 2 worldometers; 3 Globocan/Japan/factsheet; 4 McIntyre, Cancer Cell, Sept 2023; 5 Yu, Frontiers in Oncology, Jul 2021 Pancreatic Ductal Adenocarcinoma (PDAC) Represents an Area of High Unmet Need 0 5 10 15 20 25 30 35 40 45 50 5-Yr Relative Survival KRAS Mutations Are Present in ~90 -
Slide 43: RAMP 205: Designed to Identify and Evaluate RP2D
43 DLT: dose - limiting toxicity; RP2D: recommended phase 2 dose; CT: computed tomography; ECOG: European Cooperative Oncology Group; MRI: magnetic resonance imaging RAMP 205: Designed to Identify and Evaluate RP2D in Combination with Chemotherapy for Treatment of Newly Diagnosed mPDAC RAMP 205: Ong
Slide 44: RAMP 205: 12 Patients Enrolled in Each Dose Cohort
44 Updated 05/01/25 Enrolled N=60 Days Chemo Dosing Nab - Paclitaxel Gemcitabine Defactinib Avutometinib Dose Level 12 1 - 8 - 15 125 800 200 2.4 1 12 1 - 8 - 15 100 800 200 3.2 0 12 1 - 8 - 15 100 800 200 2.4 - 1 12 1 - 15 125 800 200 3.2 1a 12 1 - 15 125 1000 200 3.2 2a PART A Enrollment Summary D
Slide 45: Dose Level 1 Demonstrated a Confirmed 83% ORR
45 Source: F_TR_WATERFALL.sas Data Cut: 01 AUG 25 Dose Level 1 Demonstrated a Confirmed 83% ORR with Tumor Shrinkage Observed in All Patients Dose Level 1: Response & Disease Control Rate as of August 1, 2025 83.3% ( 10/12) Confirmed ORR, n (%) 10 (83.3) PR, n (%) 2 (16.7) SD, n (%) 0 PD, n (%) 92%
Slide 46: Encouraging Duration of Treatment for Dose Level 1
46 Source: Program:F_TX_RS_SWIMMER_DL1.sas Data Cut: 25 APR 25 Encouraging Duration of Treatment Observed to Date for Dose Level 1 Dose Level 1 Duration of Treatment Safety Population (n=12) Historical Gem/Nab PFS 95% CI mPFS Reference Study 4.5 - 5.9 5.5 MPACT N=421 Von Hoff 2013 5.3 - 5.8 5.6 NAPO
Slide 47: Patient with mPDAC Showed Substantial Tumor Shrinkage in Dose Level 1
47 Source: Dr. Lim, Siteman Cancer Center 7 Patient with mPDAC Showed Substantial Tumor Shrinkage in Dose Level 1 Before C1 After C2 After C4 After C6 metastasis primary tumor 63 year - old Female
Slide 48: AEs were Generally Manageable, Allowing Patients to Remain on Treatment
48 AEs were Generally Manageable, Allowing Patients to Remain on Treatment DL1 Treatment Emergent AE All Grades ≥ 25% / Non - laboratory AEs NAPOLI 3* (N=379) Dose Level 1 (n=12) TEAEs Grade ≥3 n (%) All Grades n (%) Grade ≥3 n (%) All Grades n (%) Preferred term 10 (3) 162 (43) 0 10 (83) Nausea 17
Slide 49: Next Step for RAMP 205
49 Next Step for RAMP 205 Expect to report an update on the safety and efficacy of expansion cohort in 1H 2026
Slide 50: Avutometinib ± Defactinib with Sotorasib in KRAS G12C mutant NSCLC
Avutometinib ± Defactinib with Sotorasib (G12Ci) in KRAS G12C mutant NSCLC
Slide 51: Addition of FAK Inhibitor Augments Efficacy of Sotorasib + Avutometinib
51 Collaboration Verastem & Mariano Barbacid , CNIO (Spain) Addition of FAK inhibitor Augments the Efficacy of Sotorasib + Avutometinib and Reverses Sotorasib Resistance in KRAS G12C NSCLC Preclinical Models AVUTOMETINIB ENHANCES SOTORASIB EFFICACY. ADDITION OF FAK INHIBITOR INDUCES DEEP TUMOR REGRE
Slide 52: RAMP 203: Phase 1/2 Trial of Avutometinib + Sotorasib ± Defactinib
52 Collaboration with Amgen, NCT05074810 DRECIST v1.1, response evaluation criteria in solid tumours version 1.1 RAMP 203: Phase 1/2 Trial of Avutometinib + LUMAKRAS TM (Sotorasib) Defactinib in KRAS G12C Advanced NSCLC Inclusion Criteria • Documented KRAS G12C mutation determined using validated te
Slide 53: RAMP 203: No DLTs Observed in First Triplet Combination Cohort
53 RAMP 203: No Dose - Limiting Toxicities (DLTs) Were Observed in the First Triplet Combination Cohort in Patients Previously Treated with a G12C Inhibitor Triplet Combination Update: • As of a November 21, 2024, data cutoff, three patients whose cancer previously progressed on a G12C inhibitor hav
Slide 54: Next Steps for RAMP 203
54 Next Steps for RAMP 203 Report an interim update on the efficacy and safety results from both the doublet and triplet combinations in Q4 2025
Slide 55: Anticipated Milestones & Financials
55 Anticipated Milestones & Financials 55
Slide 56: Execute Successful Commercial Launch in LGSOC, Followed by Meaningful Catalysts
56 Execute Successful Commercial Launch in LGSOC, Followed by Meaningful Catalysts to Expand Into Larger, Underserved Patient Populations Anticipated Milestones & Activities Program x Complete planned enrollment in RAMP 301 by end of 2025. x Announce outcome of IDMC’s sample - size re - estimation r
Slide 57: Key Financial Statistics
57 *Q3 2025 GAAP operating expenses of $51.96M less Q3 2025 stock - based compensation expense of $2.18M = $49.78M Q3 2025 non - GAAP operating expenses. **Excludes unexercised warrants (9.0M shares upon exercise) and unexercised pre - funded warrants (9.8M shares upon exercise). Key Financial Stati
Slide 58: Thank You
THANK YOU! ONCOLOGY W VERASTEM
Slide 59: AVMAPKI FAKZYNJA CO-PACK Patent Portfolio
59 OB: Orange Book Listed Patent AVMAPKI FAKZYNJA CO - PACK Patent Portfolio OB: 7,897,792 Avutometinib COM (expiry 2/9/2027) OB: 11,400,090 – Avutometinib mono dosing - (expiry 10/29/2038) PTE OB: 7,928,109 Defactinib COM US (expiry 4/17/2028) PTA PTE (Aug, 2034) OB: 8,247,411 Defactinib – genus (e
Slide 60: Experienced Senior Management Team
60 Experienced Senior Management Team Cathy Carew Chief Organizationa l Effectiveness Officer Colleen Mockbee Global Head of Regulatory Affairs and Development Nate Sanburn Chief Business Officer Dan Calkins Chief Financial Officer Matt Ros Chief Operating Officer Mike Crowther Chief Commercial & St
Slide 61: Oral VS-7375 Inhibits Tumor Growth in a Dose-Dependent Manner in KRAS G12D Models
61 Oral Administration of VS - 7375 Inhibits Tumor Growth in a Dose - Dependent Manner in KRAS G12D models AsPC - 1 PDAC Panc 04.03 PDAC GP2D CRC LS513 CRC -100 -50 0 50 100 150 200 250 300 350 R e s p o n s e @ D a y 1 4 ( % c h a n g e f r o m b a s e l i n e ) v e h i c l e V S - 7 3 7 5 1 0 m g
Slide 62: Dose Levels Achieved Steady State Target Exposures in Almost All Patients
62 Dose Levels of 400 and 600 mg QD Achieved Steady State Target Exposures in Almost all Patients Human equivalent to 100 mg/kg in mice (PR in all mice in all models) Human equivalent to 30 mg/kg in mice (Tumor regressions in all models) Human equivalent to 10 mg/kg in mice (Tumor regressions in mos
Slide 63: Cetuximab with VS-7375 Induces Complete Responses in KRAS G12D Colorectal Model
63 Addition of Cetuximab with VS - 7375 Induces Complete Responses in All Mice in a KRAS G12D Colorectal Cancer Model LS513 Colorectal Cancer Model 0 10 20 30 40 0 500 1000 1500 Tumor growth Days after first dose T u m o r v o l u m e ( m m 3 + / - S E M ) Vehicle GFH375 Cetuximab GFH375 + cetuximab
Slide 64: VS-7375 Shows Potential Best-in-Class Preclinical Properties Relative to Other G12D Inhibitors
64 NR: not reported; IP: intraperitoneal admiration; QD; once per day; QW; once per week; References: GenFleet /Verastem AACR 2024; Hallin et al (Mirati) 2022; RevMed AACR 2023; RevMed AACR 2024; Lilly ENA 2023; Lilly AACR 2024; AstraZeneca (AZ) AACR 2024; Incyte AACR 2024; Quanta AACR 2023; Tyligan